Flurry Of Marketing Collaborations Set India Deal Street Abuzz
Executive Summary
In-licensing and co-marketing/co-promotion deals are on the up in India, as local and foreign companies tango together to reach more patients and expand their business in the country's competitive market. Lupin-Boehringer, Dr Reddy’s-UCB and Glenmark-Helsinn are among the recent companies doing deals in the area.
You may also be interested in...
Asia Deal Watch: Cipla’s Latest Diabetes Partner In India Is Boehringer Ingelheim
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
Cipla Rationalizes Sri Lanka Operations
Looking to rationalize its Sri Lankan operations, Cipla buys 40% stake held by joint venture partner Citihealth Imports in Cipla Pharma Lanka. Wholly-owned subsidiary Breathe Free Sri Lanka will be its vehicle for growth in the country.
Deal Watch: Mylan Clears Up Mystery, Acquires TOBI Cystic Fibrosis Products From Novartis
Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.